Tempus AI (NASDAQ:TEM) Trading 1.8% Higher – Here’s What Happened

Tempus AI, Inc. (NASDAQ:TEM) traded up 1.8% on Friday . The company traded as high as $69.92 and last traded at $66.17. 8,634,538 shares changed hands during trading, a decline of 24% from the average session volume of 11,410,905 shares. The stock had previously closed at $64.99.

Analyst Ratings Changes

Several equities analysts have recently commented on TEM shares. Loop Capital decreased their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and upped their price objective for the company from $45.00 to $65.00 in a report on Monday, November 11th. Wolfe Research began coverage on Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Piper Sandler restated a “neutral” rating and issued a $70.00 price target (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Guggenheim began coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $58.55.

Tempus AI Price Performance

The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The firm has a fifty day simple moving average of $44.36 and a two-hundred day simple moving average of $48.84.

Insider Activity at Tempus AI

In other news, Director David R. Epstein sold 620 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total value of $25,922.20. Following the sale, the director now directly owns 27,894 shares of the company’s stock, valued at approximately $1,166,248.14. This represents a 2.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Ryan Fukushima sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $62.50, for a total transaction of $1,250,000.00. Following the transaction, the chief operating officer now directly owns 962,442 shares of the company’s stock, valued at approximately $60,152,625. This represents a 2.04 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,058,072 shares of company stock worth $90,719,375.

Institutional Investors Weigh In On Tempus AI

Several large investors have recently added to or reduced their stakes in TEM. First Horizon Advisors Inc. purchased a new stake in shares of Tempus AI during the 3rd quarter valued at $30,000. FNY Investment Advisers LLC purchased a new stake in Tempus AI during the fourth quarter valued at about $67,000. IFP Advisors Inc bought a new stake in Tempus AI during the fourth quarter worth about $76,000. US Bancorp DE purchased a new position in shares of Tempus AI in the 4th quarter worth about $80,000. Finally, Vestor Capital LLC bought a new position in shares of Tempus AI during the 3rd quarter valued at about $153,000. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.